<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">HET</journal-id>
<journal-id journal-id-type="hwp">sphet</journal-id>
<journal-id journal-id-type="nlm-ta">Hum Exp Toxicol</journal-id>
<journal-title>Human &amp; Experimental Toxicology</journal-title>
<issn pub-type="ppub">0960-3271</issn>
<issn pub-type="epub">1477-0903</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0960327112446817</article-id>
<article-id pub-id-type="publisher-id">10.1177_0960327112446817</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Perindopril protects against streptozotocin-induced hyperglycemic myocardial damage/alterations</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Patel</surname>
<given-names>BM</given-names>
</name>
<xref ref-type="aff" rid="aff-0960327112446817"/>
<xref ref-type="corresp" rid="corresp1-0960327112446817"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Agarwal</surname>
<given-names>SS</given-names>
</name>
<xref ref-type="aff" rid="aff-0960327112446817">
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bhadada</surname>
<given-names>SV</given-names>
</name>
<xref ref-type="aff" rid="aff-0960327112446817">
</xref>
</contrib>
<aff id="aff-0960327112446817">Institute of Pharmacy, Nirma University, Ahmedabad, India</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0960327112446817">Bhoomika M. Patel, Institute of Pharmacy, Nirma University, Sarkhej-Gandhinagar Highway, Ahmedabad 382 481, Gujarat, India Email: <email>drbhoomikampatel@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>11</month>
<year>2012</year>
</pub-date>
<volume>31</volume>
<issue>11</issue>
<fpage>1132</fpage>
<lpage>1143</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>High blood pressure, obesity, abnormal lipid profile, which often coexist with diabetes, tend to be associated with preclinical cardiovascular abnormalities and may contribute to the association of diabetes with cardiovascular events. Many studies have proved that streptozotocin (STZ) is responsible for type-2-diabetes-induced cardiovascular complications. Long-term perindopril therapy in patients with hypertension and diabetes has been observed to correct carotid remodeling by reducing hypertrophy. We studied the effect of perindopril (1 mg/kg/d orally [po]) on cardiovascular complications in neonatal model of rats, which was induced by administering STZ (90 mg/kg, intraperitoneally [ip]), in 5-d-old wistar rats and cardiac hypertrophy induced by isoprenaline (ISO; 5 mg/kg, ip) for 10 d. Various biochemical, cardiac, and hemodynamic parameters were measured at the end of 8 weeks of treatment in diabetes model and 10 d in hypertrophy model. STZ produced hyperglycemia, hyperinsulinemia, dyslipidemia, hypertension, bradycardia, increased creatinine kinase (CK-MB), lactate dehydrogenase enzymes (LDH) and C-reactive protein (CRP) levels, cardiac hypertrophy, and oxidative stress. Chronic treatment with perindopril significantly prevented STZ-induced hyperglycemia and hyperinsulinemia and controlled dyslipdemia in diabetic rats. Further, perindopril produced a significant reduction in elevated levels of CRP, LDH, and CK. STZ-induced hypertension and bradycardia were also prevented by perindopril treatment. Perindopril also produced beneficial effect by preventing cardiac hypertrophy as evident from cardiac hypertrophy index and left ventricular hypertrophic index. Perindopril also prevented STZ-induced oxidative stress. Similar results were obtained in ISO-induced cardiac hypertrophic model, which confirms the beneficial role of perindopril in cardiac hypertrophy. In conclusion, our data from both studies suggest that perindopril produced beneficial effect on cardiac complications.</p>
</abstract>
<kwd-group>
<kwd>Perindopril</kwd>
<kwd>type-2 diabetes mellitus</kwd>
<kwd>ISO</kwd>
<kwd>cardiac hypertrophy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0960327112446817">
<title>Introduction</title>
<p>Hypertension is very frequently associated with diabetic subjects, that is about 50% of diabetes patients, irrespective of whether they are type-1 or type-2, are hypertensive, and they contribute appreciably to cardiovascular morbidity and mortality by the acceleration of diabetic microvascular and macrovascular complications.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112446817">1</xref>
</sup> High blood pressure (BP), obesity, and abnormal lipid profile, which often coexist with diabetes, tend to be associated with preclinical cardiovascular abnormalities and may contribute to the association of diabetes with cardiovascular events.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112446817">2</xref>
</sup> Among patients with type-2 diabetes, coronary heart disease, myocardial infarction (MI), stroke and peripheral vascular disease are few important causes of mortality and morbidity.<sup>
<xref ref-type="bibr" rid="bibr3-0960327112446817">3</xref>
</sup> Individuals with hypertension and diabetes have accelerated progression of these complications, and management of hypertension in these patients reduces the risks and progression of diabetes-associated complications.<sup>
<xref ref-type="bibr" rid="bibr4-0960327112446817">4</xref>
</sup>
</p>
<p>Many studies have proved that streptozotocin (STZ) is responsible for type-2-diabetes-induced cardiovascular complications. STZ enters the β cell via a glucose transporter (GLUT2) and causes alkylation of DNA. DNA damage induces activation of poly–adenosine diphosphate (ADP) ribosylation, a process that is more important for the diabetogenicity of STZ than DNA damage itself. Poly-ADP ribosylation leads to depletion of cellular nicotinamide adenine dinucleotide (NAD+) and adenosine triphosphate (ATP). Enhanced ATP dephosphorylation after STZ treatment supplies a substrate for xanthine oxidase, resulting in the formation of superoxide radicals. Consequently, hydrogen peroxide and hydroxyl radicals are also generated. Furthermore, STZ liberates toxic amounts of nitric oxide that inhibits aconitase activity and participates in DNA damage. As a result of the STZ action, β cells undergo the destruction by necrosis.<sup><xref ref-type="bibr" rid="bibr5-0960327112446817">5</xref>
</sup></p>
<p>In hypertensive patients, increased angiotensin II (Ang II) is known to impair insulin intracellular signaling<sup><xref ref-type="bibr" rid="bibr6-0960327112446817">6</xref></sup> and pancreatic islet structure.<sup><xref ref-type="bibr" rid="bibr7-0960327112446817">7</xref></sup> It has been suggested that Ang II may have a deleterious effect on glucose metabolism by increasing reactive oxygen species (ROS) and inducing inflammation, decreasing blood flow in many tissue beds, and stimulating the sympathetic nervous system.<sup><xref ref-type="bibr" rid="bibr8-0960327112446817">8</xref></sup> Hypertension and impaired glucose tolerance leads to decrease in arterial compliance and structural and functional cardiac changes such as left ventricular hypertrophy (LVH) and left ventricular diastolic dysfunction.<sup><xref ref-type="bibr" rid="bibr9-0960327112446817">9</xref>,<xref ref-type="bibr" rid="bibr10-0960327112446817">10</xref></sup></p>
<p>The antihypertensive efficacy of perindopril, a potent angiotensin-converting enzyme inhibitor (ACE) inhibitor, is well documented. Approximately 65% of patients attained a diastolic BP of &lt;90 mmHg after 4 or 6 weeks of treatment; after 6 months, this had increased to more than 94% of patients in two of the studies.<sup><xref ref-type="bibr" rid="bibr11-0960327112446817">11</xref>,<xref ref-type="bibr" rid="bibr12-0960327112446817">12</xref></sup> Long-term perindopril therapy in patients with hypertension and diabetes has been observed to correct carotid remodeling by reducing carotid artery wall hypertrophy and increasing internal diameter.<sup><xref ref-type="bibr" rid="bibr13-0960327112446817">13</xref></sup> During the Diabetes Artery Perindopril Hypertension Normalization Excess Stiffness (DAPHNET) study, in which 57 patients with hypertension and type-2 diabetes were randomized to perindopril 4 mg/d or 8 mg/d, a dose-dependent reduction in carotid artery stiffness was observed that was independent of BP reduction.<sup><xref ref-type="bibr" rid="bibr14-0960327112446817">14</xref></sup> In a double-blind, 1-year, parallel trial comparing perindopril to atenolol in untreated hypertensive subjects, perindopril increased small artery diameter and reduced the ratio of media thickness to lumen diameter, whereas atenolol had no effect.<sup><xref ref-type="bibr" rid="bibr15-0960327112446817">15</xref></sup> In experimental animal studies, perindopril demonstrated protective effects against aortic endothelial cells<sup><xref ref-type="bibr" rid="bibr16-0960327112446817">16</xref></sup> and endothelium-dependent relaxation.<sup><xref ref-type="bibr" rid="bibr17-0960327112446817">17</xref></sup> Perindopril also enhanced myocardial angiogenesis in a model of metabolic syndrome in rats<sup><xref ref-type="bibr" rid="bibr18-0960327112446817">18</xref></sup> and demonstrated an antitrophic effect in mesenteric arteries in diabetic rats.<sup><xref ref-type="bibr" rid="bibr19-0960327112446817">19</xref></sup> In rats with STZ-induced diabetes, perindopril attenuated mesenteric vascular hypertrophy and it was suggested that this antitrophic effect resulted from the inhibition of transforming growth factor (TGF) expression.<sup><xref ref-type="bibr" rid="bibr20-0960327112446817">20</xref></sup> In SHR diabetic rats, perindopril produced an improvement in insulin sensitivity, prevented dyslipidemia and cardiac dysfunction associated with STZ-induced diabetes in Wistar and SHR rats.<sup><xref ref-type="bibr" rid="bibr21-0960327112446817">21</xref></sup> Despite these, direct study of perindopril in type-2 diabetic complications is not reported. Hence, in the present investigation, we have evaluated the effect of perindopril on cardiovascular complications associated with type-2 diabetes. Simultaneously we have analyzed the direct effect of perindopril on cardiac hypertrophy.</p>
</sec>
<sec id="section2-0960327112446817" sec-type="materials|methods">
<title>Materials and methods</title>
<p>The protocol of the experiment was approved by institutional animal ethics committee as per the guidance of committee for the purpose of control and supervision of experiments on animals (CPCSEA), Ministry of social justice and Empowerment, Government of India (Protocol No: IPS/PCOL/MPH10/003, Dated January 23, 2010). Animals used in the experiment were obtained from Zydus-Cadila Pharmaceuticals Ltd. All biochemical diagnostic kits were procured from Labcare Diagnostics Pvt. Ltd., India.</p>
<sec id="section3-0960327112446817">
<title>Isoprenaline-induced cardiac hypertrophy</title>
<p>Cardiac hypertrophy was induced by intraperitonial injection of isoprenaline (ISO; 5mg/kg/d) once daily for 10 d. Sprague Dawley rats of either sex were randomly divided into 4 groups: control (CON), control treated with perindopril (COP), disease control (DIC) and disease treated with perindopril (DIP). Perindopril was dissolved in distilled water and administered orally at a dose of 1 mg/kg/d with food and water <italic>ad libitum</italic>.</p>
</sec>
<sec id="section4-0960327112446817">
<title>Neonatal type-2 diabetes</title>
<p>Five-day-old Wistar neonates of either sex were injected with 90 mg/kg intraperitoneal (ip) STZ (Sigma Ltd., USA) in 0.9% sodium chloride solution. CON neonates received equivalent amount of isotonic saline. The neonates were left with their own mothers and weaned at 4 weeks of age. Twelve weeks after the injection of STZ, the animals were checked for fasting glucose levels with the help of available diagnostic kit (Labcare Diagnostics Pvt. Ltd., India). The animals showing fasting glucose levels &gt;170 mg/dl were considered as diabetic and divided into 4 groups: CON, COP, DIC and DIP. Perindopril was dissolved in distilled water and administered orally at a dose of 1 mg/kg/d with food and water <italic>ad libitum</italic> for 8 weeks.</p>
</sec>
<sec id="section5-0960327112446817">
<title>Blood sample collection and serum analysis</title>
<p>At the end of 10th day and 8 weeks of treatment, blood was collected from the retro orbital plexuses under light ether anesthesia. Serum samples were analyzed for glucose (GLUCOSE-SLR enzymatic colorimetric test GOD-POD), cholesterol (CHOLESTEROL-SLR enzymatic colorimetric test), high-density lipoprotein–cholesterol (HDL-C; HDL CHOLESTEROL direct enzymatic colorimetric, Liquid), triglycerides (TRIGLYCERIDES enzymatic colorimetric test—GPO PAP), C-reactive protein (CRP; CRP-SRL enzymatic colorimetric test), lactate dehydrogenase (LDH; LDH-SLR kinetic test) and creatinine kinase (CK-MB; CK-MB-SLR measurement of CK-MB activity serum and plasma) spectrophotometrically (Shimadzu UV-1601, Japan). Serum insulin was estimated for diabetic model by radioimmunoassay technique using diagnostic kits obtained from Board of Radiation and Isotope Technologay, Mumbai, India, using gamma counter (Packard, USA).</p>
</sec>
<sec id="section6-0960327112446817">
<title>Hemodynamic and cardiac parameters</title>
<p>Hemodynamic parameter viz. BP, heart rate, rate of pressure development and decay were recorded by invasive method of carotid artery cannulation (Iworx 118 System Inc., USA). After withdrawal of blood samples from retro-orbital plexus and recording hemodynamic parameters, animals were sacrificed, heart and femur were excised, and extraneous tissues were separated. Wet weight of the entire heart, left ventricle and length of femur was recorded to calculate the index of cardiac hypertrophy as wet heart weight to femur length ratio and the LVH index as left ventricular weight (LVW) to heart weight ratio. As described earlier, quantification of LV glutathione (GSH)<sup><xref ref-type="bibr" rid="bibr22-0960327112446817">22</xref></sup> and malondialdehyde (MDA) levels<sup><xref ref-type="bibr" rid="bibr23-0960327112446817">23</xref></sup> was carried out.</p>
</sec>
<sec id="section7-0960327112446817">
<title>Reduced GSH measurement</title>
<p>LV tissue was homogenized in 50 mmol/L Tris-HCI buffer (pH 7.4). The homogenate was centrifuged sequentially at 10,000<italic>g</italic> for 20 min, then at 100,000<italic>g</italic> for 60 min. To 0.5 ml of tissue supernatant, 1.5 ml of 0.2 mol/L Tris-HCI buffer (20 mmol/L EDTA, pH 8.2), 0.1 ml of 0.01 mol/L of 5,5’-dithiobis-(2-nitrobenzoic acid) and 7.9 ml of methanol were added. The mixture was incubated at 37°C with occasional shaking for 30 min. The mixture was then centrifuged at 3,000<italic>g</italic> for 15 min and the absorbance of the supernatant was determined at 412 nm.<sup><xref ref-type="bibr" rid="bibr22-0960327112446817">22</xref></sup></p>
</sec>
<sec id="section8-0960327112446817">
<title>MDA measurement</title>
<p>The supernatant, 0.5 mL, of homogenized LV tissue and 2.5 ml of 10% trichloracetic acid were added into the tubes and mixed. After incubating for 15 min at 90°C and cooling with cold water the mixture was centrifuged at 3000 rpm for 10 min. Two milliliters of supernatant were taken and 1 ml of 0.675% TBA was added. The tubes were sealed and incubated at 90°C for 15 min and then cooled to room temperature. The optical density was measured at 532 nm by a spectrophotometer.<sup><xref ref-type="bibr" rid="bibr23-0960327112446817">23</xref></sup></p>
</sec>
<sec id="section9-0960327112446817">
<title>Statistical analysis</title>
<p>Results are expressed as mean ± SEM. Statistical differences between the means of the various groups were evaluated using Student’s <italic>t</italic> test by SPSS 16 software. Data were considered statistically significant at <italic>p</italic> &lt; 0.05.</p>
</sec>
</sec>
<sec id="section10-0960327112446817">
<title>Results</title>
<sec id="section11-0960327112446817">
<title>General features</title>
<p>Diabetic rats showed significant decrease in body weight at the end of eighth week as compared to the CON group. Chronic treatment with perindopril did not alter the body weight of CON rats. Diabetic rats also showed significant increase in food and water intake at the end of eighth week as compared to the CON group. Chronic treatment with perindopril produced a significant decrease in food and water intake (<xref ref-type="table" rid="table1-0960327112446817">Table 1</xref>).</p>
<table-wrap id="table1-0960327112446817" position="float">
<label>Table 1.</label>
<caption>
<p>Effects of perindopril on glucose, insulin and cardiac parameters<sup>a</sup></p></caption>
<graphic alternate-form-of="table1-0960327112446817" xlink:href="10.1177_0960327112446817-table1.tif"/>
<table>
<thead>
<tr>
<th>Parameters</th>
<th>CON</th>
<th>COP</th>
<th>DIC</th>
<th>DIP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose (mg/dl)</td>
<td>95.63 ± 2.4</td>
<td>91.56 ± 1.8</td>
<td>240.48 ± 8.4<sup>b</sup>
</td>
<td>151.24 ± 5.6<sup>c</sup>
</td>
</tr>
<tr>
<td>Insulin (μU/ml)</td>
<td>42.21 ± 2.7</td>
<td>42.0 ± 1.5</td>
<td>62.27 ± 4.27<sup>b</sup>
</td>
<td>52.04 ± 0.94<sup>c</sup>
</td>
</tr>
<tr>
<td>CK-MB (U/l)</td>
<td>19.40 ± 0.27</td>
<td>19.44 ± 0.67</td>
<td>53.25 ± 0.28<sup>b</sup>
</td>
<td>23.25 ± 0.07<sup>c</sup>
</td>
</tr>
<tr>
<td>LDH (U/l)</td>
<td>1238.6 ± 19.8</td>
<td>1197.7 ± 24</td>
<td>2290.06 ± 30.3<sup>b</sup>
</td>
<td>1543.7 ± 22.8<sup>c</sup>
</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>1.24 ± 0.02</td>
<td>1.57 ± 0.05</td>
<td>12.41 ± 0.2<sup>b</sup>
</td>
<td>5.338 ± 0.27<sup>c</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0960327112446817">
<p>Each group contains 6 numbers of animals.</p>
</fn>
<fn id="table-fn2-0960327112446817">
<p><sup>a</sup> Values are expressed as Mean ± SEM.</p>
</fn>
<fn id="table-fn3-0960327112446817">
<p><sup>b</sup> Significantly different from control (<italic>P</italic> &lt; 0.05).</p>
</fn>
<fn id="table-fn4-0960327112446817">
<p><sup>c</sup> Significantly different from diabetic control group (<italic>P</italic> &lt; 0.05).</p>
</fn>
<fn id="table-fn5-0960327112446817">
<p>CON, control; COP, control treated with perindopril; DIC, diseased control; DIP, diseased treated with perindopril; CRP, C-reactive protein; LDH, lactate dehydrogenase; CK-MB, creatinine kinase.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section12-0960327112446817">
<title>Biochemical parameters</title>
<p>STZ-induced diabetic rats were found to exhibit significant hyperglycemia and hyperinsulinamia as compared to the CON rats. Chronic treatment with perindopril produced significant decrease in elevated serum glucose and insulin levels.</p>
<p>There was a significant increase in total cholesterol, very-low-density lipoprotein (VLDL), atherogenic index and triglycerides levels, and significant decrease in HDL-cholesterol levels in STZ diabetic rats as well as hypertrophic rats compared to the CON rats. Chronic treatment with perindopril showed a significant reduction in the levels of total cholesterol, VLDL, atherogenic index and TG, with a significant increase in HDL-C levels in both the models (<xref ref-type="table" rid="table2-0960327112446817">Table 2</xref>).</p>
<table-wrap id="table2-0960327112446817" position="float">
<label>Table 2.</label>
<caption>
<p>Effect of perindopril on lipid profile<sup>a</sup></p></caption>
<graphic alternate-form-of="table2-0960327112446817" xlink:href="10.1177_0960327112446817-table2.tif"/>
<table>
<thead>
<tr>
<th>Parameters</th>
<th>DISEASE</th>
<th>CON</th>
<th>COP</th>
<th>DIC</th>
<th>DIP</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="2">Serum cholesterol (mg/dl)</td>
<td>Hypertrophic</td>
<td>41.35 ± 5.43</td>
<td>45.1 ± 5.12</td>
<td>86.23 ± 5<sup>b</sup>
</td>
<td>47.29 ± 3.0<sup>c</sup>
</td>
</tr>
<tr>
<td>Diabetic</td>
<td>51.29 ± 1.5</td>
<td>51.56 ± 1.7</td>
<td>77.83 ± 1.9<sup>b</sup>
</td>
<td>59.12 ± 1.2<sup>c</sup>
</td>
</tr>
<tr>
<td rowspan="2">HDL-cholesterol (mg/dl)</td>
<td>Hypertrophic</td>
<td>38.36 ± 1.11</td>
<td>36.60 ± 1.21</td>
<td>26.34 ± 0.81<sup>b</sup>
</td>
<td>34.98 ± 1.8<sup>c</sup>
</td>
</tr>
<tr>
<td>Diabetic</td>
<td>39.66 ± 1.2</td>
<td>38.55 ± 1.2</td>
<td>16.92 ± 0.65<sup>b</sup>
</td>
<td>33.02 ± 1.4<sup>c</sup>
</td>
</tr>
<tr>
<td rowspan="2">Serum triglyceride (mg/dl)</td>
<td>Hypertrophic</td>
<td>129.19 ± 13.86</td>
<td>121.29 ± 13.9</td>
<td>276.96 ± 12.21<sup>b</sup>
</td>
<td>161.37 ± 9.1<sup>c</sup>
</td>
</tr>
<tr>
<td>Diabetic</td>
<td>135.6 ± 3.2</td>
<td>129.05 ± 3.3</td>
<td>280.8 ± 2.9<sup>b</sup>
</td>
<td>172.9 ± 3.5<sup>c</sup>
</td>
</tr>
<tr>
<td rowspan="2">VLDL levels (mg/dl)</td>
<td>Hypertrophic</td>
<td>25.83 ± 2.1</td>
<td>24.25 ± 1.8</td>
<td>55.39 ± 1.37<sup>b</sup>
</td>
<td>32.27 ± 1.93<sup>c</sup>
</td>
</tr>
<tr>
<td>Diabetic</td>
<td>27.12 ± 1.22</td>
<td>25.8 ± 2.2</td>
<td>56.16 ± 1.43<sup>b</sup>
</td>
<td>34.58 ± 2.34<sup>c</sup>
</td>
</tr>
<tr>
<td rowspan="2">Atherosclerosis index (Units)</td>
<td>Hypertrophic</td>
<td>0.53 ± .02</td>
<td>0.526 ± .03</td>
<td>1.02 ± .021<sup>b</sup>
</td>
<td>0.672 ± .032<sup>c</sup>
</td>
</tr>
<tr>
<td>Diabetic</td>
<td>0.539 ± .011</td>
<td>0.525 ± .032</td>
<td>1.21 ± .018<sup>b</sup>
</td>
<td>0.716 ± .037<sup>c</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0960327112446817">
<p>Each group contains 6 numbers of animals.</p>
</fn>
<fn id="table-fn7-0960327112446817">
<p><sup>a</sup> Values are expressed as Mean ± SEM.</p>
</fn>
<fn id="table-fn8-0960327112446817">
<p><sup>b</sup> Significantly different from control (<italic>p</italic> &lt; 0.05).</p>
</fn>
<fn id="table-fn9-0960327112446817">
<p><sup>c</sup> Significantly different from diabetic control group (<italic>p</italic> &lt; 0.05).</p>
</fn>
<fn id="table-fn10-0960327112446817">
<p>CON, control; COP, control treated with perindopril; DIC, diseased control; DIP, diseased treated with perindopril; HDL, high-density lipoprotein; VLDL, very-low-density lipoprotein.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section13-0960327112446817">
<title>Cardiovascular parameters</title>
<sec id="section14-0960327112446817">
<title>Serum cardiac biomarkers</title>
<p>STZ-induced diabetes produced a significant increase in the levels of serum LDH, CK and CRP as compared to CON rats. Chronic treatment with perindopril significantly reduced the elevated levels of serum LDH, CK and CRP in diabetic rats (<xref ref-type="table" rid="table1-0960327112446817">Table 1</xref>).</p>
</sec>
<sec id="section15-0960327112446817">
<title>Cardiac parameters</title>
<p>The cardiac hypertrophy and left ventricular weight (LVW) to heart weight ratio which is a measure of LVH index was significantly high in hypertrophic and diabetic animals as compared to DIC animals (<xref ref-type="fig" rid="fig1-0960327112446817">Figure 1A</xref> and B). Chronic treatment with perindopril significantly reduced cardiac hypertrophy index and LVH index of diabetic and hypertrophic rats. LVW to total body weight (LVW/TBW) and LVW to right ventricle weight (LWV/RVW) ratios were also found to be significantly higher in both hypertrophic and diabetic rats than that of the the CON rats. Chronic treatment with perindopril significantly reduced the LVW/TBW and LWV/RVW ratios of diabetic and hypertrophic rats (<xref ref-type="table" rid="table3-0960327112446817">Table 3</xref>).</p>
<fig id="fig1-0960327112446817" position="float">
<label>Figure 1.,B,</label>
<caption>
<p>A, Effect of perindopril on the change in cardiac hypertrophy index. Each bar represents mean ± SEM of six experiments. *Significantly different from control. <sup>#</sup>Significantly different from DIC. B, Effect of perindopril on the change in left ventricular hypertrophy index. Each bar represents mean ± SEM of six experiments. *Significantly different from control. <sup>#</sup>Significantly different from DIC. CON, control animals; COP, control animals treated with perindopril (1 mg/kg/d); DIB, diseased animals; DIP, diseased animals treated with perindopril (1 mg/kg/d).</p>
</caption>
<graphic alternate-form-of="fig1-0960327112446817" xlink:href="10.1177_0960327112446817-fig1.tif"/>
</fig>
<table-wrap id="table3-0960327112446817" position="float">
<label>Table 3.</label>
<caption>
<p>Effect of perindopril on hemodynamic and cardiac parameters<sup>a</sup></p></caption>
<graphic alternate-form-of="table3-0960327112446817" xlink:href="10.1177_0960327112446817-table3.tif"/>
<table>
<thead>
<tr>
<th>Parameters</th>
<th>DISEASE</th>
<th>CON</th>
<th>COP</th>
<th>DIC</th>
<th>DIP</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="2">Heart rate (bpm)</td>
<td>Hypertrophic</td>
<td>342 ± 7</td>
<td>345 ± 4</td>
<td>314 ± 3<sup>b</sup>
</td>
<td>334 ± 6<sup>c</sup>
</td>
</tr>
<tr>
<td>Diabetic</td>
<td>333 ± 12</td>
<td>343 ± 3</td>
<td>245 ± 6<sup>b</sup>
</td>
<td>305 ± 4<sup>c</sup>
</td>
</tr>
<tr>
<td rowspan="2">Blood pressure (mmHg)</td>
<td>Hypertrophic</td>
<td>122 ± 1</td>
<td>116 ± 1</td>
<td>161 ± 4<sup>b</sup>
</td>
<td>132 ± 1<sup>c</sup>
</td>
</tr>
<tr>
<td>Diabetic</td>
<td>122 ± 5</td>
<td>118 ± 4</td>
<td>165 ± 3<sup>b</sup>
</td>
<td>132 ± 4<sup>c</sup>
</td>
</tr>
<tr>
<td rowspan="2">LVW/RVW</td>
<td>Hypertrophic</td>
<td>3.4 ± 0.06</td>
<td>3.65 ± 0.05</td>
<td>7.9 ± 0.05<sup>b</sup>
</td>
<td>5.12 ± 0.04<sup>c</sup>
</td>
</tr>
<tr>
<td>Diabetic</td>
<td>3.8 + 0.02</td>
<td>3.72 + 0.03</td>
<td>8.1 ± 0.07</td>
<td>5.23 + 0.06</td>
</tr>
<tr>
<td rowspan="2">LVW/BW ratio</td>
<td>Hypertrophic</td>
<td>2.13 ± 0.015</td>
<td>2.14 ± 0.023</td>
<td>2.93 ± 0.09<sup>b</sup>
</td>
<td>2.82 ± 0.063<sup>c</sup>
</td>
</tr>
<tr>
<td>Diabetic</td>
<td>2.514 + 0.03</td>
<td>2.575 + 0.1</td>
<td>3.72 + 0.1<sup>b</sup>
</td>
<td>3.13 + 0.1<sup>c</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-0960327112446817">
<p>Each group contains 6 numbers of animals.</p>
</fn>
<fn id="table-fn12-0960327112446817">
<p><sup>a</sup> Values are expressed as mean ± SEM.</p>
</fn>
<fn id="table-fn13-0960327112446817">
<p><sup>b</sup> Significantly different from control (<italic>p</italic> &lt; 0.05).</p>
</fn>
<fn id="table-fn14-0960327112446817">
<p><sup>c</sup> Significantly different from diabetic control group (<italic>p</italic> &lt; 0.05).</p>
</fn>
<fn id="table-fn15-0960327112446817">
<p>CON, control; COP, control treated with perindopril; DIC, diseased control; DIP, diseased treated with perindopril; LVW, left ventricular weight; RVW, right ventricular weight; BW, body weight.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section16-0960327112446817">
<title>Oxidative stress</title>
<p>STZ-induced diabetes and ISO produced a significant increase in serum MDA levels as compared to CON rats (<xref ref-type="fig" rid="fig2-0960327112446817">Figure 2A</xref>). Chronic treatment with perindopril significantly reduced the elevated serum MDA in diseased rats. STZ-induced diabetes and ISO also produced a significant decrease in serum GSH levels as compared to CON rats. Chronic treatment with perindopril significantly increased the reduced serum GSH in diseased rats (<xref ref-type="fig" rid="fig2-0960327112446817">Figure 2B</xref>).</p>
<fig id="fig2-0960327112446817" position="float">
<label>Figure 2.</label>
<caption>
<p>A, Effect of perindopril on serum glutathione levels. Each bar represents mean ± SEM of six experiments. *Significantly different from control. <sup>#</sup>Significantly different from DIC. Figure .2. B, Effect of perindopril on lipid peroxidation. Each bar represents mean ± SEM of six experiments. *Significantly different from Control. <sup>#</sup>Significantly different from DIC. CON, control animals; COP, control animals treated with perindopril (1 mg/kg/d); DIB, diseased animals; DIP, diseased animals treated with perindopril (1 mg/kg/d).</p>
</caption>
<graphic alternate-form-of="fig2-0960327112446817" xlink:href="10.1177_0960327112446817-fig2.tif"/>
</fig>
</sec>
</sec>
<sec id="section17-0960327112446817">
<title>Hemodynamic parameters</title>
<p>STZ-induced diabetic rats exhibited significantly increase in BP and significantly decrease in heart rate. Chronic treatment with perindopril in diabetic rats exhibited significant decrease in BP and significant increase in heart rate (<xref ref-type="table" rid="table3-0960327112446817">Table 3</xref>). Rate of pressure development and decay was significantly decreased in diabetic control rats. Treatment with perindopril significantly increased the rate of pressure development and decay (<xref ref-type="fig" rid="fig3-0960327112446817">Figure 3</xref>). Similar results were also found in ISO-induced cardiac hypertrophy model.</p>
<fig id="fig3-0960327112446817" position="float">
<label>Figure 3.</label>
<caption>
<p>Effect of perindopril on the rate of pressure development and decay. Each bar represents mean ± SEM of six experiments. *Significantly different from Control. <sup>#</sup>Significantly different from disease control. CON, control animals; COP, control animals treated with Perindopril (1 mg/kg/d); DIB, diseased animals; DIP, diseased animals treated with perindopril (1 mg/kg/d).</p>
</caption>
<graphic alternate-form-of="fig3-0960327112446817" xlink:href="10.1177_0960327112446817-fig3.tif"/>
</fig>
</sec>
</sec>
<sec id="section18-0960327112446817">
<title>Discussion</title>
<p>Hypertensive diabetics have been reported to have more cardiovascular disease with 6–7 time higher mortality rate compared to normotensive diabetics <sup><xref ref-type="bibr" rid="bibr24-0960327112446817">24</xref><xref ref-type="bibr" rid="bibr25-0960327112446817"/>–<xref ref-type="bibr" rid="bibr26-0960327112446817">26</xref></sup> In the present investigation, we found that STZ produced cardinal signs and characteristics of diabetes, viz. loss of body weight, polyphagia, polyuria and polydipsia. Chronic treatment with perindopril significantly decreased polydipsia and polyphagia.</p>
<p>Insulin resistance and hyperinsulinemia have been postulated to play a significant role in the etiology of hypertension.<sup><xref ref-type="bibr" rid="bibr27-0960327112446817">27</xref></sup> Insulin resistance and hyperinsulinemia appear to increase the risks of diabetes, dyslipidemia and hypertension,<sup><xref ref-type="bibr" rid="bibr28-0960327112446817">28</xref></sup> and are implicated in atherogenesis, either via the increase in proinflammatory cytokines implicated in insulin resistance or via the direct proliferative effects of insulin itself on arterial smooth muscle cells.<sup><xref ref-type="bibr" rid="bibr29-0960327112446817">29</xref></sup> In the present investigation, STZ-induced diabetic rats exhibited significantly increased glucose and insulin levels, and chronic treatment with perindopril in diabetic rats significantly decreased the insulin and glucose levels. Ang II is responsible for blocking the differentiation of adipocytes, leading to accumulation of lipids in muscle, liver and pancreas and, in turn, reducing insulin sensitivity.<sup><xref ref-type="bibr" rid="bibr30-0960327112446817">30</xref></sup> Thus, perindopril, being an ACE inhibitor, might prevent ANG-II-induced phosphorylation of insulin, thereby controlling glucose and insulin levels. In a genetically obese animal model of type-2 diabetes, blockade of the renin angiotensin aldosterone system (RAAS) with perindopril attenuated changes in islet cell structure and insulin secretion.<sup><xref ref-type="bibr" rid="bibr31-0960327112446817">31</xref></sup> Fogari et al.<sup><xref ref-type="bibr" rid="bibr32-0960327112446817">32</xref></sup> found that perindopril, but not the angiotensin receptor blocker losartan, improved insulin sensitivity and reduced fibrinogen levels in overweight patients with hypertension. Thus, our reports are in consistence with several clinical reports suggesting beneficial role of perindopril in glycemic control.</p>
<p>Hypertriglyceridemia and low HDL-cholesterol levels are common in patients with type-2 diabetes or insulin resistance.<sup><xref ref-type="bibr" rid="bibr33-0960327112446817">33</xref></sup> In insulin-resistant state, endothelial cell lipoprotein lipase activity is decreased, as is the conversion of cholesterol ester–enriched VLDL to LDL, which is injurious to endothelial cells after receptor-mediated uptake<sup><xref ref-type="bibr" rid="bibr34-0960327112446817">34</xref></sup> and contribute to endothelial dysfunction.<sup><xref ref-type="bibr" rid="bibr35-0960327112446817">35</xref></sup> In the present investigation, we have also found that serum cholesterol and triglyceride levels were significantly increased in hypertrophic and STZ-induced diabetic rats and treatment with perindopril significantly reduced the elevated cholesterol and triglyceride levels. Various studies suggest that renin–angiotensin system is responsible for hyperlipidemia and atherosclerotic disease.<sup><xref ref-type="bibr" rid="bibr36-0960327112446817">36</xref>,<xref ref-type="bibr" rid="bibr37-0960327112446817">37</xref></sup> Endothelial dysfunction occurs when there is an upset in the balance of Ang II and growth factors. Ang II facilitates oxidation of LDL and its uptake by scavenger receptor on monocytes/macrophages and upregulates lipooxygenase as a basis of enhanced endothelial uptake of oxidized LDL.<sup><xref ref-type="bibr" rid="bibr38-0960327112446817">38</xref></sup> Thus, perindropril, being an ACE inhibitor, might inhibit the Ang II-mediated oxidation of LDL. Fennessy et al.<sup><xref ref-type="bibr" rid="bibr39-0960327112446817">39</xref></sup> have reported that administration of perindopril during the 6 weeks of cholesterol feeding reduced lipid accumulation in developing atheromatous plaques of the carotid artery and in fatty streaks of the aorta in rabbit model of cholesterol-induced atherosclerosis. Thus, our reports are in consistence with the other studies that perindopril prevents dyslipidemia, which in turn suggests its beneficial role in endothelial dysfunction and atherosclerotic diseases.</p>
<p>CRP, an acute phase reactant, produced mainly by liver and selectively binds to LDL, is found within atheromatous plaques and enhances complement activation.<sup><xref ref-type="bibr" rid="bibr40-0960327112446817">40</xref></sup> CRP levels are elevated in type-2 diabetes.<sup><xref ref-type="bibr" rid="bibr41-0960327112446817">41</xref></sup> In a similar study, Goyal and coworkers found that STZ-administered group possessed high level of CRP, a important cardiac biomarker.<sup><xref ref-type="bibr" rid="bibr42-0960327112446817">42</xref></sup> In present study, we found a significant rise in CRP level in STZ-induced diabetic rats as compared to normal rats. Treatment with perindopril significantly decreased CRP levels in diabetic rats. Ang II has significant proinflammatory actions in the vascular wall, inducing the production of ROS, inflammatory cytokines, and adhesion molecules, elevating the CRP levels. Enhanced production of angiotensinogen, in turn, supplies more substrate to the activated vascular ras angiotensin system (RAS), wherein the locally produced Ang II synergizes with oxidized lipid to perpetuate atherosclerotic vascular inflammation and increases CRP levels.<sup><xref ref-type="bibr" rid="bibr43-0960327112446817">43</xref></sup> Perindopril, being an ACE-inhibitor, inhibits Ang II-induced proinflammation and thereby decreases the CRP levels. This suggests that perindopril may serve as an important inhibitor of inflammatory cytokines in the myocardium.</p>
<p>The CK-MB is part of total CK and more specific for cardiac muscle than other striated muscle. CK-MB and LDH levels are reported to be increased in animal model of diabetes induced by STZ.<sup><xref ref-type="bibr" rid="bibr44-0960327112446817">44</xref></sup> In our study, we found significant increase in LDH and CK levels in STZ-induced diabetic rats as compared to normal rats. Treatment with perindopril significantly reduced LDH and CK levels and further substantiates its beneficial effect by reducing the cardiovascular risk in diabetes mellitus. The activities of LDH and CK as well as lactate concentrations in the coronary venous effluent were reduced by 39.3%, 50%, and 60.6%, respectively, after chronic treatment with perindopril in stroke-prone SHR hypertensive rats, indicating the beneficial effect in cardiac damage.<sup><xref ref-type="bibr" rid="bibr45-0960327112446817">45</xref></sup></p>
<p>Diabetes is associated with the activation of the RAAS and systemic nervous system (SNS), leading to compensatory changes in the size and shape of the cardiac chambers through cellular hypertrophy or remodeling. It has been reported that STZ induced cardiac hypertrophy, aggravating the cardiovascular complications.<sup><xref ref-type="bibr" rid="bibr46-0960327112446817">46</xref></sup> A total of 72% of the diabetic patients are found to have LVH, whereas only 32% of the nondiabetic patients have LVH. LVH does not usually occur in diabetes unless hypertension coexists. Consequently, left ventricular mass index was greater in patients with hypertension and diabetes mellitus than in those without diabetes mellitus.<sup><xref ref-type="bibr" rid="bibr47-0960327112446817">47</xref></sup> Also the ISO injection causes hypertrophic effect on heart via TGF-β<sup><xref ref-type="bibr" rid="bibr48-0960327112446817">48</xref></sup> and stimulation of protein synthesis.<sup><xref ref-type="bibr" rid="bibr49-0960327112446817">49</xref></sup> In the present study, cardiac hypertrophy index was found to be increased in both hypertrophic and STZ-induced diabetic hearts. Heart weight to body weight ratio and LVW/RVW ratio were also found to be higher in diseased hearts than control hearts in both models. Treatment with perindopril significantly decreased cardiac hypertrophy index, LVH index, heart weight to body weight ratio and LVW/RVW ratio in diseased rats. Ang II is reported to cause hypertrophy of cardiac myocytes and hyperplasia of cardiac nonmyocytes.<sup><xref ref-type="bibr" rid="bibr50-0960327112446817">50</xref></sup> In STZ-induced diabetic rats with type-1 diabetes, perindopril attenuated mesenteric vascular hypertrophy, and it was suggested that this antitrophic effect resulted from inhibition of TGF-β expression.<sup><xref ref-type="bibr" rid="bibr51-0960327112446817">51</xref></sup> Thus, perindopril might inhibit the expression of hypertrophic genes and thus provide beneficial role in cardiac dysfunction.</p>
<p>STZ causes increased production of ROS due to the autooxidation of monosaccharides, leading to the production of superoxide and hydroxyl radicals.<sup><xref ref-type="bibr" rid="bibr52-0960327112446817">52</xref></sup> Reduced antioxidant capacity has been reported in cardiac tissue from diabetic animals.<sup><xref ref-type="bibr" rid="bibr53-0960327112446817">53</xref></sup> In present study, we found a significant increase in pro-oxidant (MDA) levels and decrease in antioxidant (GSH) levels in STZ-induced diabetic and hypertrophic rats. Chronic treatment with perindopril showed a significant increase in antioxidant (GSH) and significant decrease in MDA levels in STZ-induced diabetic rats. Both experimental and clinical studies have provided functional evidence for stimulation of the renin–angiotensin system and simultaneously for activation of an NAD(P)H oxidase in the vascular wall. Activation of NAD(P)H oxidase and increased superoxide within the vascular wall have important implications for both the progression of atherosclerosis and the development of clinical event.<sup><xref ref-type="bibr" rid="bibr47-0960327112446817">47</xref>,<xref ref-type="bibr" rid="bibr54-0960327112446817">54</xref></sup> The ACE inhibitors reduce Ang II levels and increase bradykinin levels, suggesting that perindopril have important implications for vascular oxidative stress.<sup><xref ref-type="bibr" rid="bibr48-0960327112446817">48</xref>,<xref ref-type="bibr" rid="bibr55-0960327112446817">55</xref></sup> It has been established that perindopril reduced oxidative stress and increases the plasma antioxidant capacity in a prospective, randomized, parallel group study assessed in hypertensive patients.<sup><xref ref-type="bibr" rid="bibr55-0960327112446817">55</xref></sup> Thus, perindopril may be beneficial in oxidative stress and lipid peroxidation during MI.</p>
<p>Increase in BP after treatment with STZ and ISO has been reported by several studies.<sup><xref ref-type="bibr" rid="bibr56-0960327112446817">56</xref></sup> Hypertension is very frequently associated with diabetic subjects,<sup><xref ref-type="bibr" rid="bibr2-0960327112446817">2</xref></sup> that is about 50% of patients with diabetes, irrespective of whether they are type-1 or type-2, are hypertensive. Several reasons are postulated for the development of hypertension in diabetes. One of the reasons for hypertension is loss of the autoregulatory (RAAS and SNS) response, which can amplify the damaging effects of systemic BP on small blood vessels.<sup><xref ref-type="bibr" rid="bibr57-0960327112446817">57</xref></sup> Further, potentiation of bradykinin, a powerful vasodilator that enhances insulin signaling<sup><xref ref-type="bibr" rid="bibr58-0960327112446817">58</xref></sup> and translocation of the glucose transporter in skeletal muscle, may be responsible for some of the hemodynamic and nonhemodynamic effects of ACE inhibition.<sup><xref ref-type="bibr" rid="bibr59-0960327112446817">59</xref>,<xref ref-type="bibr" rid="bibr60-0960327112446817">60</xref></sup> Of the ACE inhibitors, perindopril has the capacity to increase the ratio of bradykinin and Ang II.<sup><xref ref-type="bibr" rid="bibr61-0960327112446817">61</xref></sup> In the present study of chronic treatment with ACE inhibitors, perindopril significantly decreased the BP in treated rats compared to diseased rats in both models. Oral administration of perindopril has been demonstrated to be an effective BP-lowering agent in adult patients with mild-to-moderate hypertension in numerous randomized clinical trials.<sup><xref ref-type="bibr" rid="bibr62-0960327112446817">62</xref></sup> Bradycardia has been frequently observed in STZ diabetic rats<sup><xref ref-type="bibr" rid="bibr63-0960327112446817">63</xref></sup> as well as in ISO-induced rats.<sup><xref ref-type="bibr" rid="bibr64-0960327112446817">64</xref></sup> The development of STZ-induced bradycardia has been attributed to a downregulation of myocardial beta adrenoceptors, hypothyroidism,<sup><xref ref-type="bibr" rid="bibr65-0960327112446817">65</xref></sup> depression of myocardial calcium metabolism,<sup><xref ref-type="bibr" rid="bibr66-0960327112446817">66</xref></sup> reduced uptake of calcium by the sarcoplasmic reticulum and concomitantly depression of SR-calcium ATPase activity.<sup><xref ref-type="bibr" rid="bibr67-0960327112446817">67</xref></sup> It is well established that Ang II exerts an inhibitory influence on baroreceptor reflex control of heart rate after either intravenous administration in several species.<sup><xref ref-type="bibr" rid="bibr68-0960327112446817">68</xref></sup> Perindopril is an ACE inhibitor and it is possible that it may attenuate the Ang II-mediated inhibition of baroreceptor reflex. This may be the possible mechanism involved in the  increased heart rate by perindopril treatment in hypertrophic rats in both the models.</p>
<p>In the present investigation, STZ and ISO injection decreased the rate of pressure development and decay, which is the direct indicator of myocardial contractility dysfunctioning and cardiac fibrosis. In present study, chronic treatment with perindopril significantly increased the rate of pressure development and decay. The data presented in a very interesting study clearly demonstrate that overexpression of the fast-twitch skeletal muscle SR Ca-ATPase and increase in the rate of pressure development and decay (+dp/dt and −dp/dt) in the mammalian heart results in significantly elevated Ca transport function and cardiac contractile performance. This study suggests that the SERCA pump level is a critical determinant of myocardial contractility.<sup><xref ref-type="bibr" rid="bibr69-0960327112446817">69</xref></sup> STZ-induced diabetes in animal models causes changes in myocardial cellular calcium transport and contractile proteins, which result in subclinical myocardial contractility dysfunction.<sup><xref ref-type="bibr" rid="bibr70-0960327112446817">70</xref>,<xref ref-type="bibr" rid="bibr71-0960327112446817">71</xref></sup> Thus, perindopril appears to be beneficial in cardiac dysfunctioning.</p>
<p>From the above investigation we can concluded that perindopril prevents not only the STZ-induced metabolic abnormalities but also cardiovascular complications. Perindopril is also found to be beneficial in hypertrophy, which can make it an optimistic treatment in type-2 diabetes as well as in cardiac hypertrophy-induced cardiovascular complications.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1-0960327112446817"><label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0960327112446817">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Balon</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Mark</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans</article-title>. <source>J Clin Invest</source> <year>1991</year>; <volume>87</volume>: <fpage>2246</fpage>–<lpage>2252</lpage>.</citation>
</ref>
<ref id="bibr2-0960327112446817">
<label>2.</label>
<citation citation-type="journal">
<collab collab-type="author">The Hypertension in Diabetes Stydy Group</collab>. <article-title>Hypertension in Diabetes Study (HDS): 1. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications</article-title>. <source>J Hypertens</source> <year>1993</year>; <volume>11</volume>: <fpage>309</fpage>–<lpage>317</lpage>.</citation>
</ref>
<ref id="bibr3-0960327112446817">
<label>3.</label>
<citation citation-type="journal">
<collab collab-type="author">Markku Laakso</collab>. <article-title>Hyperglycemia and cardiovascular disease in type 2 diabetes</article-title>. <source>Diabetes</source> <year>1999</year>; <volume>48</volume>: <fpage>197</fpage>–<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr4-0960327112446817">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Helmy</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>ADVANCE in management of vascular complications of diabetes</article-title>. <source>Lancet</source> <year>2007</year>; <volume>370</volume>: <fpage>829</fpage>–<lpage>840</lpage>.</citation>
</ref>
<ref id="bibr5-0960327112446817">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Portha</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Levacher</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Picon</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rosselin</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Diabetogenic effect of STZ in the rat during the perinatal period</article-title>. <source>Diabetes</source> <year>1974</year>; <volume>23</volume>: <fpage>889</fpage>–<lpage>895</lpage>.</citation>
</ref>
<ref id="bibr6-0960327112446817">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsueh</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>RE</given-names>
</name>
</person-group>. <article-title>Cardiovascular risk continuum: implications of insulin resistance and diabetes</article-title>. <source>Am J Med</source> <year>1998</year>; <volume>105</volume>: <fpage>4</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr7-0960327112446817">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tikellis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wookey</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Candido</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Andrikopoulos</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>ME</given-names>
</name>
</person-group>. <article-title>Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat</article-title>. <source>Diabetes</source> <year>2004</year>; <volume>53</volume>: <fpage>989</fpage>–<lpage>997</lpage>.</citation>
</ref>
<ref id="bibr8-0960327112446817">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ingelfinger</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Solomon</surname>
<given-names>CG</given-names>
</name>
</person-group>. <article-title>Angiotensin- converting-enzyme inhibitors for impaired glucose tolerance – is there still hope?</article-title> <source>N Engl J Med</source> <year>2006</year>; <volume>355</volume>: <fpage>1608</fpage>–<lpage>1610</lpage>.</citation>
</ref>
<ref id="bibr9-0960327112446817">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salmasi</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Dancy</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Glucose intolerance: the hidden danger in hypertensives!</article-title> <source>Int Angiol</source> <year>2005</year>; <volume>24</volume>: <fpage>207</fpage>–<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr10-0960327112446817">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burnier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zanchi</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes</article-title>. <source>J Hypertens</source> <year>2006</year>; <volume>24</volume>: <fpage>11</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr11-0960327112446817">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fressinaud</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Berrut</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gallois</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Antihypertensive activity and acceptability based upon clinical and laboratory parameters of perindopril: chief results in 23,460 mild to moderate hypertension patients treated for 6 months in general practice (French)</article-title>. <source>Ann Cardiol Angéiol</source> <year>1993</year>; <volume>42</volume>: <fpage>51</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr12-0960327112446817">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suraniti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Berrut</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Marre</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fressinaud</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Antihypertensive efficacy and acceptability of perindopril in elderly hypertensive patients</article-title>. <source>Am J Cardiol</source> <year>1993</year>; <volume>71</volume>: <fpage>28E</fpage>–<lpage>31E</lpage>.</citation>
</ref>
<ref id="bibr13-0960327112446817">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girerd</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Giannattasio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Moulin</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long term antihypertensive treatment: the PERICLES study</article-title>. <source>J Am Coll Cardiol</source> <year>1998</year>; <volume>31</volume>: <fpage>1064</fpage>–<lpage>1073</lpage>.</citation>
</ref>
<ref id="bibr14-0960327112446817">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tropeano</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Boutouyrie</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pannier</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Brachial pressure-independent reduction in carotid stiffness after long term angiotensin converting enzyme inhibition in diabetic hypertensives</article-title>. <source>Hypertension</source> <year>2006</year>; <volume>48</volume>: <fpage>1</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr15-0960327112446817">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thybo</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aalkjaer</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Efficacy of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension</article-title>. <source>Hypertension</source> <year>1995</year>; <volume>25</volume>: <fpage>474</fpage>–<lpage>481</lpage>.</citation>
</ref>
<ref id="bibr16-0960327112446817">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>XY</given-names>
</name>
</person-group>. <article-title>Changes of ultrastructure and function of the aortic endothelium in streptozocin-diabetic rats and effect of perindopril</article-title>. <source>Bull Hunan Med Univ</source> <year>2001</year>; <volume>26</volume>: <fpage>41</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr17-0960327112446817">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<name>
<surname>You</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Protective effect of perindopril on dysfunction of endothelium- dependent relaxation in diabetic rats</article-title>. <source>Bull Hunan Med Univ</source> <year>2000</year>; <volume>25</volume>: <fpage>122</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr18-0960327112446817">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toblli</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>DeRosa</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Di Gennaro</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats</article-title>. <source>Am J Hypertens</source> <year>2004</year>; <volume>17</volume>: <fpage>172</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr19-0960327112446817">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rumble</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Komers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>ME</given-names>
</name>
</person-group>. <article-title>Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat</article-title>. <source>J Hypertens</source> <year>1996</year>; <volume>14</volume>: <fpage>601</fpage>–<lpage>607</lpage>.</citation>
</ref>
<ref id="bibr20-0960327112446817">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Rumble</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Jandeleit</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies</article-title>. <source>Metabolism</source> <year>1998</year>; <volume>47</volume>: <fpage>24</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr21-0960327112446817">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goyal</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Lakkad</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Bangaru</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>MV</given-names>
</name>
</person-group>. <article-title>Effects of chronic treatment with enalapril on STZ-induced diabetic rats</article-title>. <source>Pharmacol Res Commun</source> <year>1997</year>; <volume>9</volume>: <fpage>133</fpage>–<lpage>139</lpage>.</citation>
</ref>
<ref id="bibr22-0960327112446817">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moron</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Depierre</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Mannervik</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver</article-title>. <source>Biochim Biophys Acta</source> <year>1979</year>; <volume>528</volume>: <fpage>67</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr23-0960327112446817">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slater</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Sawyer</surname>
<given-names>BC</given-names>
</name>
</person-group>. <article-title>The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions in vitro. General features of the systems used</article-title>. <source>Biochem J</source> <year>1971</year>; <volume>123</volume>: <fpage>8</fpage>.</citation>
</ref>
<ref id="bibr24-0960327112446817">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siragy</surname>
<given-names>HM</given-names>
</name>
</person-group>. <article-title>ADVANCE in management of vascular complications of diabetes</article-title>. <source>Lancet</source> <year>2007</year>; <volume>370</volume>: <fpage>829</fpage>–<lpage>840</lpage>.</citation>
</ref>
<ref id="bibr25-0960327112446817">
<label>25.</label>
<citation citation-type="journal">
<collab collab-type="author">UK Prospective Diabetes Study (UKPDS) Group</collab>. <article-title>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)</article-title>. <source>Lancet</source> <year>1999</year>; <volume>354</volume>: <fpage>602</fpage>.</citation>
</ref>
<ref id="bibr26-0960327112446817">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cowie</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>MI</given-names>
</name>
</person-group>. <article-title>Diabetes and decline in heart disease mortality in U.S. adults</article-title>. <source>J Am Med Assoc</source> <year>1999</year>; <volume>281</volume>: <fpage>1291</fpage>–<lpage>1297</lpage>.</citation>
</ref>
<ref id="bibr27-0960327112446817">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reaven</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Relationship between BP, plasma insulin and triglyceride concentration, and insulin action in spontaneously hypertensive rats and Wistar Kyoto rats</article-title>. <source>Am J Hypertension</source> <year>1991</year>; <volume>4</volume>: <fpage>34</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr28-0960327112446817">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fogari</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zoppi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lazzari</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Preti</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>ACE inhibition but not Ang II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients</article-title>. <source>J Cardiovas Pharmacol</source> <year>1998</year>; <volume>32</volume>: <fpage>616</fpage>–<lpage>620</lpage>.</citation>
</ref>
<ref id="bibr29-0960327112446817">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sjöholm</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nyström</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Endothelial inflammation in insulin resistance</article-title>. <source>Lancet</source> <year>2005</year>; <volume>365</volume>: <fpage>610</fpage>–<lpage>612</lpage>.</citation>
</ref>
<ref id="bibr30-0960327112446817">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Janke</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gorzelniak</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Engeli</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Angiotensin blockade prevents type 2 diabetes by formation of fat cells</article-title>. <source>Hypertension</source> <year>2002</year>; <volume>40</volume>: <fpage>609</fpage>–<lpage>611</lpage>.</citation>
</ref>
<ref id="bibr31-0960327112446817">
<label>31.</label>
<citation citation-type="journal">
<collab collab-type="author">ALLHAT Collaborative Research Group</collab>. <article-title>Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic</article-title>. <source>JAMA</source> <year>2002</year>; <volume>288</volume>: <fpage>2981</fpage>–<lpage>2997</lpage>.</citation>
</ref>
<ref id="bibr32-0960327112446817">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taskinen</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus</article-title>. <source>Diabetes</source> <year>1992</year>; <volume>41</volume>: <fpage>12</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr33-0960327112446817">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tesfamariam</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C</article-title>. <source>J Clin Invest</source> <year>1991</year>; <volume>87</volume>: <fpage>1643</fpage>–<lpage>1648</lpage>.</citation>
</ref>
<ref id="bibr34-0960327112446817">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsueh</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>PW</given-names>
</name>
</person-group>. <article-title>Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus</article-title>. <source>Hypertension</source> <year>1992</year>; <volume>20</volume>: <fpage>253</fpage>–<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr35-0960327112446817">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laragh</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Review course. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension</article-title>. <source>Am J Hypertens</source> <year>2001</year>; <volume>41</volume>: <fpage>84</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr36-0960327112446817">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dzau</surname>
<given-names>VJ</given-names>
</name>
</person-group>. <article-title>Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis</article-title>. <source>Hypertension</source> <year>2001</year>; <volume>37</volume>: <fpage>1047</fpage>–<lpage>1052</lpage>.</citation>
</ref>
<ref id="bibr37-0960327112446817">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Philips</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Sawamura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>JL</given-names>
</name>
</person-group>. <article-title>Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by Ang II type 1 receptor activation</article-title>. <source>Circ Res</source> <year>1999</year>; <volume>84</volume>: <fpage>1043</fpage>–<lpage>1049</lpage>.</citation>
</ref>
<ref id="bibr38-0960327112446817">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fennessy</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mendelsohn</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease</article-title>. <source>Clin Exp Pharmacol Physiol</source> <year>2007</year>; <volume>23</volume>: <fpage>30</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr39-0960327112446817">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhakdi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Toprzewski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Klouche</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hemmes</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Complement and atherogenesis. Binding of CRP to degraded, nonoxidised LDL enhance complement activation</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>1999</year>; <volume>19</volume>: <fpage>2348</fpage>–<lpage>2354</lpage>.</citation>
</ref>
<ref id="bibr40-0960327112446817">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pradhan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Manson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rifai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Buring</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Ridker</surname>
<given-names>PM</given-names>
</name>
</person-group>. <article-title>Creactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus</article-title>. <source>JAMA</source> <year>2001</year>; <volume>286</volume>: <fpage>327</fpage>–<lpage>334</lpage>.</citation>
</ref>
<ref id="bibr41-0960327112446817">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goyal</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Parmar</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Goyal</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>AA</given-names>
</name>
</person-group>. <article-title>Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type-2 diabetic rats</article-title>. <source>Pharmacol Rep</source> <year>2011</year>; <volume>63</volume>(<issue>4</issue>): <fpage>956</fpage>–<lpage>966</lpage>.</citation>
</ref>
<ref id="bibr42-0960327112446817">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brasier</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Recinos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Eledrisi</surname>
<given-names>MS</given-names>
</name>
</person-group>. <article-title>Vascular inflammation and the renin angiotensin system</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2002</year>; <volume>22</volume>: <fpage>1257</fpage>–<lpage>1266</lpage>.</citation>
</ref>
<ref id="bibr43-0960327112446817">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goyal</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Mesariya</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Goyal</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>AA</given-names>
</name>
</person-group>. <article-title>Effect of telmisartan on cardiovascular complications associated with STZ- induced diabetic rats</article-title>. <source>Mol Cell Bioch</source> <year>2008</year>; <volume>314</volume>(<issue>1-2</issue>): <fpage>123</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr44-0960327112446817">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gohlke</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kuwer</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bartenbach</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schnell</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Unger</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Effect of low-dose treatment with perindopril on cardiac function in stroke-prone spontaneously hypertensive rats: role of bradykinin</article-title>. <source>J Cardiovasc Pharmacol</source> <year>1994</year>; <volume>24</volume>: <fpage>462</fpage>–<lpage>469</lpage>.</citation>
</ref>
<ref id="bibr45-0960327112446817">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goyal</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Bhadada</surname>
<given-names>SV</given-names>
</name>
</person-group>. <article-title>Comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril on diabetes induced cardiovascular complications in type 1 diabetes in rats</article-title>. <source>Int J Diabetes Metab</source> <year>2011</year>; <volume>19</volume>(<issue>1</issue>): <fpage>11</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr46-0960327112446817">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grossman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Shemesh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shamiss</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thaler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rosenthal</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Left ventricular mass in diabetes-hypertension</article-title>. <source>Arch Intern Med</source> <year>1992</year>; <volume>152</volume>: <fpage>1001</fpage>–<lpage>1004</lpage>.</citation>
</ref>
<ref id="bibr47-0960327112446817">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guzik</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>West</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors</article-title>. <source>Circ Res</source> <year>2000</year>; <volume>86</volume>: <fpage>E85</fpage>–<lpage>E90</lpage>.</citation>
</ref>
<ref id="bibr48-0960327112446817">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laursen</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Rajagopalan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Galis</surname>
<given-names>ZS</given-names>
</name>
</person-group>. <article-title>Role of superoxide in Ang II–induced but not catecholamine- induced hypertension</article-title>. <source>Circulation</source> <year>1997</year>; <volume>95</volume>: <fpage>588</fpage>–<lpage>593</lpage>.</citation>
</ref>
<ref id="bibr49-0960327112446817">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hefti</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Harder</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Eppenberger</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Schaub</surname>
<given-names>MC</given-names>
</name>
</person-group>. <article-title>Signaling pathways in cardiac myocyte hypertrophy</article-title>. <source>J Mol Cell Cardiol</source> <year>1997</year>; <volume>9</volume>: <fpage>2873</fpage>–<lpage>2892</lpage>.</citation>
</ref>
<ref id="bibr50-0960327112446817">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Rumble</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Jandeleit</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>RE</given-names>
</name>
</person-group>. <article-title>Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies</article-title>. <source>Metabolism</source> <year>1998</year>; <volume>47</volume>: <fpage>24</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr51-0960327112446817">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolff</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>RT</given-names>
</name>
</person-group>. <article-title>Glucose autoxidation and protein modification</article-title>. <source>Biochem J</source> <year>1987</year>; <volume>245</volume>:<fpage>243</fpage>–<lpage>250</lpage>.</citation>
</ref>
<ref id="bibr52-0960327112446817">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Low</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Nickander</surname>
<given-names>KK</given-names>
</name>
</person-group>. <article-title>Oxygen free radical effects in sciatic nerve in experimental diabetes</article-title>. <source>Diabetes</source> <year>1991</year>; <volume>40</volume>: <fpage>873</fpage>–<lpage>877</lpage>.</citation>
</ref>
<ref id="bibr53-0960327112446817">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hermenegildo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Raya</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Roma</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>FJ</given-names>
</name>
</person-group>. <article-title>Decreased glutathione peroxidase activity m sciatic nerve of alloxan-induced diabetic and its correlation with blood glucose levels</article-title>. <source>Neurochem Res</source> <year>1993</year>; <volume>18</volume>: <fpage>893</fpage>–<lpage>896</lpage>.</citation>
</ref>
<ref id="bibr54-0960327112446817">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warnholtz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nickenig</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Increased NADH oxidase–mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system</article-title>. <source>Circulation</source> <year>1999</year>; <volume>99</volume>: <fpage>2027</fpage>–<lpage>2033</lpage>.</citation>
</ref>
<ref id="bibr55-0960327112446817">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghiadoni</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Magagna</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Versari</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>Different effect of antihypertensive drugs on conduit artery endothelial function</article-title>. <source>Hypertension</source> <year>2003</year>; <volume>41</volume>: <fpage>1281</fpage>–<lpage>1286</lpage>.</citation>
</ref>
<ref id="bibr56-0960327112446817">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Funakawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Okahara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Imanishi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Komori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tochino</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Renin angiotensin system and prostacyclin biosynthesis in STZ diabetic rats</article-title>. <source>Eur J Pharmacol</source> <year>1983</year>; <volume>94</volume>: <fpage>27</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr57-0960327112446817">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tooke</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Goh</surname>
<given-names>KL</given-names>
</name>
</person-group>. <article-title>Endothelinopathy precedes type 2 diabetes</article-title>. <source>Diabetes Care</source> <year>1998</year>; <volume>12</volume>: <fpage>2047</fpage>–<lpage>2049</lpage>.</citation>
</ref>
<ref id="bibr58-0960327112446817">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Taguchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Uehara</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Bradykinin potentiates insulinstimulated glucose uptake and enhances insulin signal through the bradykinin B2 receptor in dog skeletal muscle and rat L6 myoblasts</article-title>. <source>Eur J Endocrinol</source> <year>1998</year>; <volume>138</volume>: <fpage>344</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr59-0960327112446817">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dietze</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Wcklmayr</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rett</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Henriksen</surname>
<given-names>EJ</given-names>
</name>
</person-group>. <article-title>Potential role of bradykinin in forearm muscle metabolism in humans</article-title>. <source>Diabetes</source> <year>1996</year>; <volume>45</volume>(<issue>suppl 1</issue>): <fpage>S110</fpage>–<lpage>S114</lpage>.</citation>
</ref>
<ref id="bibr60-0960327112446817">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rett</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wicklmayr</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dietze</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Häring</surname>
<given-names>HU</given-names>
</name>
</person-group>. <article-title>Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin</article-title>. <source>Diabetes</source> <year>1996</year>; <volume>45</volume>: <fpage>S66</fpage>–<lpage>S69</lpage>.</citation>
</ref>
<ref id="bibr61-0960327112446817">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campbell</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Kladis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Duncan</surname>
<given-names>AM</given-names>
</name>
</person-group>. <article-title>Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides</article-title>. <source>Hypertension</source> <year>1994</year>; <volume>23</volume>: <fpage>439</fpage>–<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr62-0960327112446817">
<label>62.</label>
<citation citation-type="journal">
<collab collab-type="author">PROGRESS Collaborative Group</collab>. <article-title>Effects of a perindopril-based BP lowering regimen on cardiac outcomes among patients with cerebrovascular disease</article-title>. <source>Eur Heart J</source> <year>2003</year>; <volume>24</volume>: <fpage>475</fpage>–<lpage>484</lpage>.</citation>
</ref>
<ref id="bibr63-0960327112446817">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goyal</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>B</given-names>
</name>
<name>
<surname>McNeill</surname>
<given-names>JH</given-names>
</name>
</person-group>. <article-title>Effects of tri-iodo-lthyronine on cardiac responses to adrenergic agonists in STZ-induced diabetic rats</article-title>. <source>Gen Pharmacol</source> <year>1987</year>; <volume>18</volume>: <fpage>357</fpage>–<lpage>362</lpage>.</citation>
</ref>
<ref id="bibr64-0960327112446817">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhargava</surname>
<given-names>HN</given-names>
</name>
<name>
<surname>Kasabdji</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>EB</given-names>
</name>
</person-group>. <article-title>Subsensitivity to noradrenaline and ISO in rabbits acutely pre-treated with morphine</article-title>. <source>Gen Pharmacol</source> <year>1977</year>; <volume>8</volume>: <fpage>257</fpage>–<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr65-0960327112446817">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baba</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Recent advances in pharmacological management of hypertension in diabetic patients with nephropathy. Effects of antihypertensive drugs on kidney function and insulin sensitivity</article-title>. <source>Drugs</source> <year>1992</year>; <volume>43</volume>: <fpage>464</fpage>–<lpage>489</lpage>.</citation>
</ref>
<ref id="bibr66-0960327112446817">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nordin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gilat</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Delayed after depolarisation and activity in ventricular muscle from rats in STZ induced diabetes</article-title>. <source>Circ Res</source> <year>1990</year>; <volume>57</volume>: <fpage>28</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr67-0960327112446817">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denton</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Randle</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Concentration of triglycerides and phospholipids in rat heart and gastronemics muscle effect of alloxan diabetes and perfusion</article-title>. <source>Bio Chem J</source> <year>1967</year>; <volume>104</volume>: <fpage>416</fpage>–<lpage>422</lpage>.</citation>
</ref>
<ref id="bibr68-0960327112446817">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliveira</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Khosla</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Campagnole-Santos</surname>
<given-names>MJ</given-names>
</name>
</person-group>. <article-title>Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats</article-title>. <source>Hypertension</source> <year>1996</year>; <volume>27</volume>: <fpage>1284</fpage>–<lpage>1290</lpage>.</citation>
</ref>
<ref id="bibr69-0960327112446817">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loukianov</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Grupp</surname>
<given-names>IL</given-names>
</name>
<etal/>
</person-group> <article-title>Enhanced myocardial contractility and increased Ca21 transport function in transgenic hearts expressing the fast-twitch skeletal muscle sarcoplasmic reticulum Ca21-ATPase</article-title>. <source>Circ Res</source> <year>1998</year>; <volume>83</volume>; <fpage>889</fpage>–<lpage>897</lpage>.</citation>
</ref>
<ref id="bibr70-0960327112446817">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ganguly</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Pierce</surname>
<given-names>GN</given-names>
</name>
<name>
<surname>Dhalla</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Dhalla</surname>
<given-names>NS</given-names>
</name>
</person-group>. <article-title>Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy</article-title>. <source>Am J Physiol</source> <year>1983</year>; <volume>244</volume>: <fpage>E528</fpage>–<lpage>E535</lpage>.</citation>
</ref>
<ref id="bibr71-0960327112446817">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giacomelli</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wiener</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Primary myocardial disease in the diabetic mouse: an ultrastructural study</article-title>. <source>Lab Invest</source> <year>1979</year>; <volume>40</volume>: <fpage>460</fpage>–<lpage>473</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>